Actively Recruiting
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Led by Sichuan University · Updated on 2025-12-08
40
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced esophageal squamous cell carcinoma (ESCC). The primary endpoints are safety, surgical conversion rate and event-free survival (EFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), and quality of life (QoL). Exploratory endpoints include biomarker analyses such as single-cell sequencing.
CONDITIONS
Official Title
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Diagnosed with locally advanced esophageal squamous cell carcinoma with or without cervical lymph node metastases
- Ability to provide fresh tumor tissue samples before treatment
- Normal major organ function
- Performance status score of 1 or less
- Use contraception if of childbearing potential
- Voluntary participation with signed informed consent
- Ability to follow study protocol and attend follow-up visits
You will not qualify if you...
- Prior antitumor chemotherapy, radiotherapy, or immunotherapy before first-line treatment
- High risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation
- Poor nutritional status
- Immune-related serious adverse events during prior radical treatment, such as Grade 3 or higher pneumonitis or myocarditis
- Symptoms or signs of interstitial lung diseases
- Severe or uncontrolled medical conditions
- Presence of other active cancers
- Other autoimmune diseases or prolonged use of immunosuppressants or steroids
- Difficulty communicating or inability to comply with long-term follow-up
- Other conditions judged unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
Z
Zhenyu Ding, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here